Innovative Pharmaceutical Biotech (HKG:0399) entered into a memorandum of understanding with Conflux Hong Kong Management to cooperate on the infrastructure and common key technologies related to the Conflux blockchain, a Tuesday Hong Kong bourse filing said.
The cooperation scope includes the research and development of innovative technologies, and exploration of application scenarios with possible equity cooperation.
Hong Kong-incorporated Conflux engages mainly in the development of blockchain technology.